Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Advanced Solid Tumors and Non-small Cell Lung Cancer
2022-503108-26-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of AGEN1777 in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events and Safety-related discontinuation and death. Started Jul 2023; status: completed.
02
Drugs
AGEN1777
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-503108-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503108-26-00.